ArticleThe journal of physical chemistry. B2025
Unveiling the Interactions of Doxorubicin with the Lipid Components of Liposomes for Its Delivery.
Article in The journal of physical chemistry. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular states and interfacial interactions at solid-liquid interfaces: advances and challenges in multimodal characterization.Beilstein journal of nanotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The characterization of drug/lipid interactions is key to developing novel and more efficient drug delivery systems. In this work, we combine electrochemical measurements, attenuated total reflection (ATR) spectroscopy, and molecular dynamics simulations to unveil the interacting mechanisms of doxorubicin (DOX) with lipid monolayers and bilayers containing a cytidine derivative nucleolipid, which serve as a model system of previously developed liposomes for DOX delivery. The nucleolipid was included in the liposome formulation to take advantage of its molecular recognition capabilities and its capacity to anchor gold nanoparticles. The compression isotherms of the Langmuir monolayers and interfacial capacitance measurements on a gold electrode modified with hybrid bilayers in the presence of DOX demonstrate the interaction of the drug with the nucleolipid polar heads. This is confirmed by computational simulations of a solvated DOX/bilayer complex, which show that the adsorption process is driven by stacking and electrostatic interactions involving the aromatic and nonaromatic moieties of DOX, respectively. Moreover, both ATR spectra of supported bilayers on silicon and simulations show that the presence of DOX does not significantly affect the tilt angles of the lipids. The system studied in this work is a promising therapeutic option for cancer treatment. The combined methodology applied to this study can serve as a reference for other studies of drug-carrier interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.